Join
Live feed
·
PRReleasevia Quantisnow
GT Biopharma Inc. logo

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

ByQuantisnow·Wall Street's wire, on your screen.
GTBP· GT Biopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GTBP (GT Biopharma Inc.) and more on Quantisnow.